Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC88 in platinum-resistant recurrent ovarian cancer
NCT06173037Phase 2Completed
- Sponsor
- RemeGen
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of misitatug blivedotin in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by RemeGen. Primary endpoint: Overall Response Rate at 2 years. Started Jan 2024; status: completed.
02
Drugs
misitatug blivedotin
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06173037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06173037.